中危甲状腺乳头状癌患者术后缓解评估以避免放射性碘残留消融的应答研究
本研究前瞻性纳入215例中危甲状腺乳头状癌患者,依据术后治疗反应联合复发风险分层与TNM分期进行三层评估,对术后达卓越缓解或不确定缓解者免于放射性碘残留消融并主动监测。中位随访23.6个月,卓越缓解比例升至82.8%,仅0.5%出现结构性不完全缓解、0.5%出现生化不完全缓解;随访超12个月的173例中,卓越缓解与不确定缓解两亚组无病生存率无显著差异(100% vs 97.9%,P=.20)。
要点
- 中危甲状腺乳头状癌术后达卓越缓解或不确定缓解者,可免于放射性碘残留消融。
- 中位随访23.6个月,卓越缓解比例由47.4%升至82.8%,不确定缓解降至16.3%。
- 随访超12个月者,卓越缓解与不确定缓解两亚组无病生存率无显著差异(100% vs 97.9%,P=.20)。
核心结论
- 通过突出术后治疗反应的三层评估,中危甲状腺乳头状癌患者术后卓越缓解与不确定缓解者免于放射性碘残留消融,在23.6个月随访期间可能呈现相似的有利应答。
研究设计与样本
- 前瞻性研究,纳入无疾病证据且术后评估为卓越缓解或不确定缓解、知情同意后免于放射性碘残留消融并主动监测的中危甲状腺乳头状癌患者,共215例。
- 排除参与其他试验或随访数据不足者。
- 主要结局指标为持续超过12个月的无疾病证据,表现为持久卓越缓解或不确定缓解。
主要发现
- 215例中,放射性碘决策时卓越缓解占47.4%(102/215),不确定缓解占52.6%(113/215)。
- 中位随访23.6个月(四分位距13.8-31.6)后,卓越缓解增至82.8%(178/215),不确定缓解降至16.3%(35/215),85例由不确定缓解转为卓越缓解。
- 仅0.5%(1/215)出现结构性不完全缓解,0.5%(1/215)出现生化不完全缓解。
- 完成2次诊断性全身扫描的94例中,中位间隔13.0个月,27.7%(26/94)观察到成功残留消融,提示诊疗一体化效应。
- 随访超过12个月的173例中,卓越缓解与不确定缓解两亚组无病生存率无显著差异(100% vs 97.9%,P=.20)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Using response to surgery when tailoring radioiodine (RAI) therapy for papillary thyroid cancer (PTC) is valued but lacks prospective validation. OBJECTIVE: To spare RAI thyroid remnant ablation among patients with intermediate-risk PTCs using 3-tiered assessments with response to surgery highlighted, in addition to the risk of the recurrence stratification and TNM staging. METHODS: Patients with no evidence of disease (NED) identified as excellent response (ER) or indeterminate response (IDR) to surgery were spared from RAI thyroid remnant ablation after informed consent and prospectively enrolled under active surveillance. Those involved in other trials or without sufficient follow-up data were excluded. Dynamic responses were followed and compared longitudinally. The main outcome measures were NED presenting as durable ER or IDR for over 12 months. RESULTS: Of the enrolled 215 patients, 47.4% (102/215) ER and 52.6% (113/215) IDR were identified regarding RAI decision-making. After a median of 23.6 (interquartile range 13.8-31.6) months, the share of ER increased to 82.8% (178/215) and IDR decreased to 16.3% (35/215), with 85 patients shifting from IDR to ER over time, only 0.5% (1/215) structural incomplete response and 0.5% (1/215) biochemical incomplete response observed. Successful remnant ablation was observed in 27.7% (26/94) of the patients completing 2 diagnostic whole-body scans after a median interval of 13.0 months, indicating a theranostic effect. In the 173 patients followed for over 12 months, the NED rate did not differ between ER and IDR subgroups (100% vs 97.9%, P = .20). CONCLUSION: Through the 3-tiered assessments with response to surgery highlighted, postoperative ER and IDR spared from RAI remnant ablation may indicate similar favorable responses in intermediate-risk patients with PTC during 23.6 months of follow-up.
引用
- Zhang X, Liu JR, Mu ZZ, et al. Response to Surgery Assessments for Sparing Radioiodine Remnant Ablation in Intermediate-Risk Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2023. PMID: 36567646. doi:10.1210/clinem/dgac745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。